Terazosin | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Terazosin | hsa00053 | Ascorbate and aldarate metabolism | 5.61E-03 | 2 | P51648, Q9UEF7 | ALDH3A2, KL | More | |
Terazosin | hsa00280 | Valine, leucine and isoleucine degradation | 4.55E-02 | 2 | P21953, P51648 | BCKDHB, ALDH3A2 | More | |
Terazosin | hsa00510 | N-Glycan biosynthesis | 3.15E-02 | 2 | P15907, Q9NR34 | ST6GAL1, MAN1C1 | More | |
Terazosin | hsa00630 | Glyoxylate and dicarboxylate metabolism | 5.34E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
Terazosin | hsa00830 | Retinol metabolism | 3.15E-02 | 1 | P00325 | ADH1B | More | |
Terazosin | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.09E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | |
Terazosin | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Terazosin | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Terazosin | hsa01524 | Platinum drug resistance | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa02010 | ABC transporters | 4.48E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Terazosin | hsa03020 | RNA polymerase | 1.31E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | |
Terazosin | hsa03040 | Spliceosome | 4.19E-02 | 5 | Q14562, O60508, P08579, Q01130, O43447 | DHX8, CDC40, SNRPB2, SFRS2, PPIH | More | |
Terazosin | hsa03450 | Non-homologous end-joining | 4.48E-03 | 1 | P78527 | PRKDC | More | |
Terazosin | hsa04010 | MAPK signaling pathway | 4.93E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa04014 | Ras signaling pathway | 7.30E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04015 | Rap1 signaling pathway | 6.14E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04022 | cGMP-PKG signaling pathway | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04024 | cAMP signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04060 | Cytokine-cytokine receptor interaction | 2.02E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa04064 | NF-kappa B signaling pathway | 2.63E-03 | 11 | P10415, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q13315, P24522, P09341 | BCL2, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, ATM, GADD45A, CXCL1 | More | |
Terazosin | hsa04068 | FoxO signaling pathway | 1.57E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa04070 | Phosphatidylinositol signaling system | 2.96E-02 | 3 | P19174, P49619, P27987 | PLCG1, DGKG, ITPKB | More | |
Terazosin | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
Terazosin | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
Terazosin | hsa04110 | Cell cycle | 1.30E-04 | 7 | P06493, P78527, P10600, P30304, P33981, P01106, Q13547 | CDK1, PRKDC, TGFB3, CDC25A, TTK, MYC, HDAC1 | More | |
Terazosin | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | |
Terazosin | hsa04141 | Protein processing in endoplasmic reticulum | 9.57E-03 | 4 | P30101, P49257, P60604, Q9H173 | PDIA3, LMAN1, UBE2G2, SIL1 | More | |
Terazosin | hsa04145 | Phagosome | 3.69E-02 | 7 | O75015, Q15080, P05164, P78380, O60603, P35443, P13765 | FCGR3B, NCF4, MPO, OLR1, TLR2, THBS4, HLA-DOB | More | |
Terazosin | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
Terazosin | hsa04218 | Cellular senescence | 1.74E-04 | 3 | P31751, P0DP23, P10600 | AKT2, CALM1, TGFB3 | More | |
Terazosin | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.83E-03 | 6 | P07550, P22694, P31751, P18848, Q13362, P0DP23 | ADRB2, PRKACB, AKT2, ATF4, PPP2R5C, CALM1 | More | |
Terazosin | hsa04350 | TGF-beta signaling pathway | 1.12E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa04370 | VEGF signaling pathway | 3.60E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa04371 | Apelin signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04380 | Osteoclast differentiation | 2.11E-03 | 2 | Q9NQC7, P31751 | CYLD, AKT2 | More | |
Terazosin | hsa04390 | Hippo signaling pathway | 1.12E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | |
Terazosin | hsa04610 | Complement and coagulation cascades | 1.91E-03 | 1 | P0C0L4 | C4A | More | |
Terazosin | hsa04612 | Antigen processing and presentation | 3.33E-04 | 8 | P13765, P48382, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Terazosin | hsa04613 | Neutrophil extracellular trap formation | 1.22E-04 | 7 | P19174, P11215, Q13547, P58876, P62807, Q16778, O60814 | PLCG1, ITGAM, HDAC1, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Terazosin | hsa04620 | Toll-like receptor signaling pathway | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa04622 | RIG-I-like receptor signaling pathway | 1.81E-02 | 1 | Q9NQC7 | CYLD | More | |
Terazosin | hsa04625 | C-type lectin receptor signaling pathway | 1.38E-05 | 3 | Q9NQC7, P31751, P0DP23 | CYLD, AKT2, CALM1 | More | |
Terazosin | hsa04630 | JAK-STAT signaling pathway | 3.20E-02 | 4 | P01106, P42224, P14784, Q13651 | MYC, STAT1, IL2RB, IL10RA | More | |
Terazosin | hsa04640 | Hematopoietic cell lineage | 4.72E-02 | 8 | P13612, P27930, P15144, P25063, P09693, P01732, P13765, P01375 | ITGA4, IL1R2, ANPEP, CD24, CD3G, CD8A, HLA-DOB, TNF | More | |
Terazosin | hsa04650 | Natural killer cell mediated cytotoxicity | 5.26E-05 | 10 | P01375, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | |
Terazosin | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
Terazosin | hsa04658 | Th1 and Th2 cell differentiation | 8.66E-06 | 13 | Q04759, P07766, P20963, P09693, P19174, P06239, P42224, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, LCK, STAT1, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | |
Terazosin | hsa04659 | Th17 cell differentiation | 5.60E-04 | 12 | Q04759, P19174, P06239, P42224, P14784, P13765, Q9HBE5, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, PLCG1, LCK, STAT1, IL2RB, HLA-DOB, IL21R, TBX21, GATA3, CD3E, CD3G, CD247 | More | |
Terazosin | hsa04660 | T cell receptor signaling pathway | 4.75E-03 | 10 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK | More | |
Terazosin | hsa04662 | B cell receptor signaling pathway | 1.60E-04 | 6 | P31751, P42338, P60033, P07948, P21854, Q8N149 | AKT2, PIK3CB, CD81, LYN, CD72, LILRA2 | More | |
Terazosin | hsa04664 | Fc epsilon RI signaling pathway | 4.79E-03 | 4 | P31751, P42338, P07948, P09917 | AKT2, PIK3CB, LYN, ALOX5 | More | |
Terazosin | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
Terazosin | hsa04722 | Neurotrophin signaling pathway | 2.83E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04724 | Glutamatergic synapse | 5.94E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | |
Terazosin | hsa04725 | Cholinergic synapse | 4.10E-02 | 3 | P63218, P50151, P42338 | GNG5, GNG10, PIK3CB | More | |
Terazosin | hsa04727 | GABAergic synapse | 1.68E-03 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
Terazosin | hsa04728 | Dopaminergic synapse | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04740 | Olfactory transduction | 9.46E-04 | 2 | Q9H255, P0DP23 | OR51E2, CALM1 | More | |
Terazosin | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
Terazosin | hsa04744 | Phototransduction | 1.81E-02 | 1 | P0DP23 | CALM1 | More | |
Terazosin | hsa04910 | Insulin signaling pathway | 9.82E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Terazosin | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Terazosin | hsa04915 | Estrogen signaling pathway | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04916 | Melanogenesis | 4.78E-02 | 1 | P0DP23 | CALM1 | More | |
Terazosin | hsa04917 | Prolactin signaling pathway | 2.41E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa04919 | Thyroid hormone signaling pathway | 1.64E-02 | 4 | P19174, P42224, Q13547, P01106 | PLCG1, STAT1, HDAC1, MYC | More | |
Terazosin | hsa04920 | Adipocytokine signaling pathway | 4.19E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa04922 | Glucagon signaling pathway | 1.79E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa04923 | Regulation of lipolysis in adipocytes | 3.01E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa04924 | Renin secretion | 6.02E-03 | 3 | P22694, P07550, P0DP23 | PRKACB, ADRB2, CALM1 | More | |
Terazosin | hsa04926 | Relaxin signaling pathway | 3.93E-04 | 9 | P42338, P63218, P50151, P18848, P22694, P49767, P14780, P30679, P49407 | PIK3CB, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, GNA15, ARRB1 | More | |
Terazosin | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
Terazosin | hsa04929 | GnRH secretion | 3.61E-03 | 3 | P42338, P31751, P49407 | PIK3CB, AKT2, ARRB1 | More | |
Terazosin | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.12E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | |
Terazosin | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | |
Terazosin | hsa04970 | Salivary secretion | 2.96E-03 | 4 | P07550, P22694, P0DP23, P49913 | ADRB2, PRKACB, CALM1, CAMP | More | |
Terazosin | hsa04971 | Gastric acid secretion | 4.78E-02 | 1 | P0DP23 | CALM1 | More | |
Terazosin | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | |
Terazosin | hsa04973 | Carbohydrate digestion and absorption | 2.41E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa05010 | Alzheimer disease | 8.59E-04 | 3 | Q00535, P0DP23, P31751 | CDK5, CALM1, AKT2 | More | |
Terazosin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.60E-03 | 4 | Q06055, Q00535, O15020, P0DP23 | ATP5G2, CDK5, SPTBN2, CALM1 | More | |
Terazosin | hsa05030 | Cocaine addiction | 4.19E-02 | 1 | Q00535 | CDK5 | More | |
Terazosin | hsa05031 | Amphetamine addiction | 6.98E-03 | 4 | P0DP23, P22694, P18848, Q13547 | CALM1, PRKACB, ATF4, HDAC1 | More | |
Terazosin | hsa05034 | Alcoholism | 6.27E-04 | 5 | Q13547, P58876, P62807, Q16778, O60814 | HDAC1, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Terazosin | hsa05133 | Pertussis | 3.51E-02 | 1 | P0C0L4 | C4A | More | |
Terazosin | hsa05140 | Leishmaniasis | 3.29E-02 | 7 | P13612, O75015, P13765, O60603, P10600, P01375, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TGFB3, TNF, NCF4 | More | |
Terazosin | hsa05142 | Chagas disease | 1.79E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05144 | Malaria | 2.19E-04 | 6 | P60033, O60603, P01375, P35443, P10600, P26718 | CD81, TLR2, TNF, THBS4, TGFB3, KLRK1 | More | |
Terazosin | hsa05145 | Toxoplasmosis | 3.59E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05146 | Amoebiasis | 6.12E-04 | 10 | P09341, P19875, P27930, P01375, O60603, P05089, P30679, P22694, P10600, P08311 | CXCL1, CXCL2, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, TGFB3, CTSG | More | |
Terazosin | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | |
Terazosin | hsa05152 | Tuberculosis | 9.92E-03 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Terazosin | hsa05161 | Hepatitis B | 2.69E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05163 | Human cytomegalovirus infection | 1.21E-02 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa05169 | Epstein-Barr virus infection | 3.90E-03 | 8 | P01106, Q13547, P42338, P07948, Q13761, O75293, P42224, P07766 | MYC, HDAC1, PIK3CB, LYN, RUNX3, GADD45B, STAT1, CD3E | More | |
Terazosin | hsa05170 | Human immunodeficiency virus 1 infection | 6.71E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa05200 | Pathways in cancer | 3.07E-02 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Terazosin | hsa05202 | Transcriptional misregulation in cancer | 2.90E-03 | 15 | Q13315, P14780, P27930, Q15744, Q16548, P11215, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, Q13547, P12980, P24522 | ATM, MMP9, IL1R2, CEBPE, BCL2A1, ITGAM, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC1, LYL1, GADD45A | More | |
Terazosin | hsa05203 | Viral carcinogenesis | 2.31E-04 | 7 | Q13547, P12814, P06493, P58876, P62807, Q16778, O60814 | HDAC1, ACTN1, CDK1, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Terazosin | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
Terazosin | hsa05210 | Colorectal cancer | 1.57E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05211 | Renal cell carcinoma | 1.46E-03 | 2 | P10600, P31751 | TGFB3, AKT2 | More | |
Terazosin | hsa05212 | Pancreatic cancer | 1.46E-03 | 2 | P31751, P10600 | AKT2, TGFB3 | More | |
Terazosin | hsa05213 | Endometrial cancer | 3.60E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa05214 | Glioma | 5.75E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Terazosin | hsa05218 | Melanoma | 3.01E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa05220 | Chronic myeloid leukemia | 1.06E-03 | 2 | P10600, P31751 | TGFB3, AKT2 | More | |
Terazosin | hsa05221 | Acute myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa05222 | Small cell lung cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa05223 | Non-small cell lung cancer | 2.41E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa05225 | Hepatocellular carcinoma | 1.35E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05226 | Gastric cancer | 7.27E-04 | 2 | P31751, P10600 | AKT2, TGFB3 | More | |
Terazosin | hsa05230 | Central carbon metabolism in cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Terazosin | hsa05231 | Choline metabolism in cancer | 1.39E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | |
Terazosin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.46E-03 | 5 | P19174, P07766, P06239, P42224, Q9HC35 | PLCG1, CD3E, LCK, STAT1, EML4 | More | |
Terazosin | hsa05310 | Asthma | 1.92E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | |
Terazosin | hsa05321 | Inflammatory bowel disease | 1.68E-05 | 8 | O60603, P01375, P10600, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, TGFB3, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
Terazosin | hsa05322 | Systemic lupus erythematosus | 1.15E-03 | 5 | P58876, P62807, Q16778, O60814, P12814 | H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, ACTN1 | More | |
Terazosin | hsa05323 | Rheumatoid arthritis | 2.24E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05332 | Graft-versus-host disease | 6.25E-04 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | |
Terazosin | hsa05410 | Hypertrophic cardiomyopathy | 8.97E-03 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | |
Terazosin | hsa05414 | Dilated cardiomyopathy | 5.18E-03 | 3 | P54284, P26678, P10600 | CACNB3, PLN, TGFB3 | More | |
Terazosin | hsa05415 | Diabetic cardiomyopathy | 3.59E-02 | 1 | P10600 | TGFB3 | More | |
Terazosin | hsa05418 | Fluid shear stress and atherosclerosis | 3.65E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |